Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 8/20 | 0.53 |
| ▸ | PTK2B | Q14289 | 5/20 | 0.53 |
| ▸ | FLT3 | P36888 | 7/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 4/20 | 0.47 |
| ▸ | ULK1 | O75385 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 3/20 | 0.46 |
| ▸ | CDK2 | P24941 | 3/20 | 0.46 |
| ▸ | IGF1R | P08069 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.46 |
| ▸ | BMX | P51813 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12235658 | 1.00 | PTK2 (0.53) | PTK2PTK2BFLT3TBK1KCNH2 | |
| SCHEMBL5576448 | 1.00 | PTK2 (0.53) | PTK2PTK2BFLT3TBK1KCNH2 | |
| SCHEMBL12235225 | 0.98 | PTK2 (0.51) | PTK2PTK2BFLT3TBK1KCNH2 | |
| SCHEMBL12234937 | 0.98 | PTK2 (0.50) | PTK2PTK2BFLT3TBK1KCNH2 | |
| SCHEMBL12234174 | 0.94 | PTK2 (0.53) | PTK2PTK2BFLT3KCNH2KIT | |
| SCHEMBL12235232 | 0.94 | PTK2 (0.49) | PTK2PTK2BFLT3TBK1KCNH2 | |
| SCHEMBL12234938 | 0.93 | PTK2 (0.52) | PTK2PTK2BFLT3KCNH2KIT | |
| SCHEMBL14621752 | 0.93 | PTK2 (0.52) | PTK2PTK2BFLT3KCNH2KIT | |
| SCHEMBL12236299 | 0.93 | PTK2 (0.51) | PTK2PTK2BFLT3KCNH2KIT | |
| SCHEMBL12234951 | 0.92 | PTK2 (0.51) | PTK2PTK2BFLT3KCNH2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289014-A1 | Combination therapy in treatment of oncological and fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-20120107304-A1 | Combination therapy in treatment of oncological and fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| WO-2011134898-A1 | NEW COMBINATION THERAPY IN TREATMENT OF ONCOLOGICAL AND FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | WO | disclosed |
| US-20110251174-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-13 | — | — | US | disclosed |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | US | disclosed |
| WO-2007003596-A1 | 2,4-DIAMINO-PYRIMIDINES USED AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107304-A1 | Combination therapy in treatment of oncological and fibrotic diseases | AURKB, AURKC, AURKA | PTK2 35/4885PTK2B 98/4885FLT3 235/4885 |
| US-20110251174-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | AURKA, AURKC, AURKB | PTK2 835/4885PTK2B 390/4885FLT3 102/4885 |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | AURKA, AURKC, AURKB | PTK2 835/4885PTK2B 390/4885FLT3 102/4885 |
| US-20130289014-A1 | Combination therapy in treatment of oncological and fibrotic diseases | AURKB, AURKC, AURKA | PTK2 35/4885PTK2B 98/4885FLT3 235/4885 |
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | AURKA, AURKC, AURKB | PTK2 835/4885PTK2B 390/4885FLT3 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.